{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:07:44Z","timestamp":1788865664208,"version":"build-2803163510"},"reference-count":66,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK117599"],"award-info":[{"award-number":["R01DK117599"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","award":["U54DK083912"],"award-info":[{"award-number":["U54DK083912"]}],"id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000183","name":"Army Research Office","doi-asserted-by":"publisher","award":["W911NF-21-1-0359"],"award-info":[{"award-number":["W911NF-21-1-0359"]}],"id":[{"id":"10.13039\/100000183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA227493"],"award-info":[{"award-number":["R01CA227493"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK104753"],"award-info":[{"award-number":["R01DK104753"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","award":["UL1TR000460"],"award-info":[{"award-number":["UL1TR000460"]}],"id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","award":["U01DK116101"],"award-info":[{"award-number":["U01DK116101"]}],"id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","award":["UM1DK100846"],"award-info":[{"award-number":["UM1DK100846"]}],"id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,4,26]]},"abstract":"<jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and podocyte lipotoxicity in experimental Alport syndrome (AS). In vitro, we found that the SGLT2 protein was expressed in human and mouse podocytes to a similar extent in tubular cells. Newly established immortalized podocytes from Col4a3 knockout mice (AS podocytes) accumulate lipid droplets along with increased apoptosis when compared to wild-type podocytes. Treatment with SGLT2i empagliflozin reduces lipid droplet accumulation and apoptosis in AS podocytes. Empagliflozin inhibits the utilization of glucose\/pyruvate as a metabolic substrate in AS podocytes but not in AS tubular cells. In vivo, we demonstrate that empagliflozin reduces albuminuria and prolongs the survival of AS mice. Empagliflozin-treated AS mice show decreased serum blood urea nitrogen and creatinine levels in association with reduced triglyceride and cholesterol ester content in kidney cortices when compared to AS mice. Lipid accumulation in kidney cortices correlates with a decline in renal function. In summary, empagliflozin reduces podocyte lipotoxicity and improves kidney function in experimental AS in association with the energy substrates switch from glucose to fatty acids in podocytes.<\/jats:p>","DOI":"10.7554\/elife.83353","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T08:00:54Z","timestamp":1683014454000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.83353","source":"Crossref","is-referenced-by-count":61,"title":["Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome"],"prefix":"10.7554","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-377X","authenticated-orcid":true,"given":"Mengyuan","family":"Ge","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Molina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ju","family":"Kim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamroop K","family":"Mallela","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Ahmad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Radiation Oncology, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Varona Santos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Al-Ali","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Mitrofanova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Sharma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01kd65564","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Precision Medicine, School of Medicine, University of Texas Health San Antonio","place":["San Antonio, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Fontanesi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Biology, University of Miami","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Merscher","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-7773","authenticated-orcid":true,"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine","place":["Miami, United States"]},{"id":[{"id":"https:\/\/ror.org\/02dgjyy92","id-type":"ROR","asserted-by":"publisher"}],"name":"Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine","place":["Miami, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"C464","DOI":"10.1152\/ajpcell.00563.2009","article-title":"Bioenergetic characterization of mouse podocytes","volume":"299","author":"Abe","year":"2010","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"bib2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.2349482","article-title":"Identification of mutations in the COL4A5 collagen gene in Alport syndrome","volume":"248","author":"Barker","year":"1990","journal-title":"Science"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/ndt\/gfac006","article-title":"Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant: a prospective cohort study","volume":"37","author":"Boeckhaus","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.celrep.2019.04.012","article-title":"Anaerobic glycolysis maintains the glomerular filtration barrier independent of mitochondrial metabolism and dynamics","volume":"27","author":"Brinkkoetter","year":"2019","journal-title":"Cell Reports"},{"key":"bib6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98720","article-title":"Sglt2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-Target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [ Na+ ] I in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovascular Research"},{"key":"bib9","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00794","article-title":"The link between the mitochondrial fatty acid oxidation derangement and kidney injury","volume":"11","author":"Console","year":"2020","journal-title":"Frontiers in Physiology"},{"key":"bib10","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph1208s25","article-title":"Measurement of cell death in mammalian cells","volume":"25","author":"Cummings","year":"2004","journal-title":"Current Protocols in Pharmacology"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nature Reviews. Nephrology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40620-020-00845-7","article-title":"Sglt2 inhibitors, sodium and off-target effects: an overview","volume":"34","author":"De Pascalis","year":"2021","journal-title":"Journal of Nephrology"},{"key":"bib13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94818","article-title":"Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits","volume":"3","author":"Ding","year":"2018","journal-title":"JCI Insight"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1172\/JCI125316","article-title":"Atp-Binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes","volume":"129","author":"Ducasa","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicologic Pathology"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"bib17","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovascular Diabetology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/hmg\/ddab022","article-title":"APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis","volume":"30","author":"Ge","year":"2021","journal-title":"Human Molecular Genetics"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney International"},{"key":"bib20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw095","article-title":"Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International workshop on Alport syndrome","volume":"32","author":"Gross","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1081\/jdi-100101961","article-title":"Contemporary diagnostic approach in Alport\u2019s syndrome","volume":"22","author":"Gr\u00fcnfeld","year":"2000","journal-title":"Renal Failure"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2337\/db13-0752","article-title":"Podocyte-Specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy","volume":"63","author":"Guzman","year":"2014","journal-title":"Diabetes"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/ijms16010924","article-title":"Lipid metabolism, apoptosis and cancer therapy","volume":"16","author":"Huang","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1073\/pnas.88.12.5096","article-title":"Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse","volume":"88","author":"Jat","year":"1991","journal-title":"PNAS"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nature Medicine"},{"key":"bib28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103162","article-title":"Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome","volume":"63","author":"Kim","year":"2021","journal-title":"EBioMedicine"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"bib30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129034","article-title":"Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2020.06.040","article-title":"Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome","volume":"98","author":"Liu","year":"2020","journal-title":"Kidney International"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.5862","article-title":"Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A\/caveolin-1\/PV-1 signaling pathway","volume":"256","author":"Locatelli","year":"2022","journal-title":"The Journal of Pathology"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1046\/j.1523-1755.2002.00379.x","article-title":"COL4A3\/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome","volume":"61","author":"Longo","year":"2002","journal-title":"Kidney International"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/CS20191276","article-title":"Sglt2 inhibitors-a potential treatment for Alport syndrome","volume":"134","author":"Mabillard","year":"2020","journal-title":"Clinical Science"},{"key":"bib35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41253-7","article-title":"Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells","volume":"9","author":"Maki","year":"2019","journal-title":"Scientific Reports"},{"key":"bib36","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiology"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2337\/db13-0399","article-title":"Cyclodextrin protects podocytes in diabetic kidney disease","volume":"62","author":"Merscher-Gomez","year":"2013","journal-title":"Diabetes"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney International"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1194\/jlr.D300024-JLR200","article-title":"A method of direct measurement for the enzymatic determination of cholesteryl esters","volume":"45","author":"Mizoguchi","year":"2004","journal-title":"Journal of Lipid Research"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/excr.1997.3739","article-title":"Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines","volume":"236","author":"Mundel","year":"1997","journal-title":"Experimental Cell Research"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/MNH.0000000000000187","article-title":"Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update","volume":"25","author":"Novikov","year":"2016","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"bib42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","volume":"66","author":"op den Kamp","year":"2022","journal-title":"Molecular Metabolism"},{"key":"bib43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123130","article-title":"Sglt2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1172\/JCI85939","article-title":"Local TNF causes nfatc1-dependent cholesterol-mediated podocyte injury","volume":"126","author":"Pedigo","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1681\/ASN.2020101442","article-title":"Identification of an altered matrix signature in kidney aging and disease","volume":"32","author":"Randles","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41556-018-0270-5","article-title":"Extracellular matrix mechanical cues regulate lipid metabolism through lipin-1 and SREBP","volume":"21","author":"Romani","year":"2019","journal-title":"Nature Cell Biology"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/ki.1986.8","article-title":"Glucose metabolism in renal tubular function","volume":"29","author":"Ross","year":"1986","journal-title":"Kidney International"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"F557","DOI":"10.1152\/ajprenal.00509.2009","article-title":"Conditionally immortalized human podocyte cell lines established from urine","volume":"298","author":"Sakairi","year":"2010","journal-title":"American Journal of Physiology-Renal Physiology"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"bib50","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqz046","article-title":"CPT1A-mediated fat oxidation","volume":"161","author":"Schlaepfer","year":"2020","journal-title":"Mechanisms, and Therapeutic Potential. Endocrinology"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.ki.5002033","article-title":"Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate","volume":"71","author":"Takahashi","year":"2007","journal-title":"Kidney International"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"F476","DOI":"10.1152\/ajprenal.00363.2006","article-title":"A primary culture of mouse proximal tubular cells, established on collagen-coated membranes","volume":"293","author":"Terryn","year":"2007","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"Sglt2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"bib56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151585","article-title":"Sodium glucose cotransporter 2 (SGLT2) plays as a physiological glucose sensor and regulates cellular contractility in rat mesangial cells","volume":"11","author":"Wakisaka","year":"2016","journal-title":"PLOS ONE"},{"key":"bib57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"Journal of Lipid Research"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"Sglt2 protein expression is increased in human diabetic nephropathy","volume":"292","author":"Wang","year":"2017","journal-title":"Journal OF Biological Chemistry"},{"key":"bib59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sciences"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/s0140-6736(61)90899-6","article-title":"Alport\u2019s syndrome of hereditary nephritis with deafness","volume":"2","author":"Williamson","year":"1961","journal-title":"Lancet"},{"key":"bib61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24890-3","article-title":"Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease","volume":"12","author":"Wright","year":"2021","journal-title":"Nature Communications"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1681\/ASN.2018020125","article-title":"Single-Cell transcriptomics of a human kidney allograft biopsy specimen defines a diverse inflammatory response","volume":"29","author":"Wu","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1681\/ASN.2018090912","article-title":"Advantages of single-nucleus over single-cell RNA sequencing of adult kidney","volume":"30","author":"Wu","year":"2019","journal-title":"Rare Cell Types and Novel Cell States Revealed in Fibrosis. J Am Soc Nephrol"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"Sglt2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"European Journal of Pharmacology"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1681\/ASN.2013111213","article-title":"Sphingomyelinase-like phosphodiesterase 3B expression levels determine podocyte injury phenotypes in glomerular disease","volume":"26","author":"Yoo","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"bib66","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-11-10","article-title":"The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility","volume":"11","author":"Zhang","year":"2014","journal-title":"Nutrition & Metabolism"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/83353\/elife-83353-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/83353\/elife-83353-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/83353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:10:02Z","timestamp":1697058602000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/83353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":66,"alternative-id":["10.7554\/eLife.83353"],"URL":"https:\/\/doi.org\/10.7554\/elife.83353","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.10.04.510832","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/2022.10.04.510832","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.83353.sa0","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.83353.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.83353.sa2","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.742632300.793598956","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e83353"}}